Member Info for Laura2022

Big buying now and I cannot buy on HL

Thanks Ralph

Is this part of the new foray into bio statistics?

Also what do you think might happen now with USA positive feedback on the personalised medicine tool from PYC ( it was mentioned in April trading statement along with DoseMeRx)

If DoseMeRx take on our technology would that be the significant move for Physiomics?

Thanks

L

The company had 2 in one week, would be good to get more next week

Good luck with your order ,it loos like on HL there is about £3,000or less on offer at 6.95p

From the most recent update

 Annualised Recurring Revenue ('ARR') increased by 7% in one month to £6.7m at the end of March.

• Contracted and recurring revenues expected to account for over 60% of total revenues.

· Q4 billings* up 23% on Q3 to £4.3m (Q3: £3.5m). Notably, Q4 included the signing of several significant multi-year contracts, with an aggregate value of £5.0m.

· Gross margin expected to increase to 61% (FY22: 59%).

Good point

I bought some stocks for high dividend (LLOYD PSN) but even they don't offset inflation

I just think that this has to be worth more than £7mln when annual recurring revenues are £6mln and growing

good morning ***an,it is currently 6.95p to buy just £500 so u think that large £50k sell was the reason why it fell 55% on monday

seems harsh given annual recurring revenues are £6mln and net assets are high

they also have a £0.5mln facility

nigel wray and directors own 50% at 42p placing

"as we have previously stated, our strategy is to grow organically and by acquisition. in the current financial market conditions, our primary focus is on organic growth and, in particular, in positioning our cyber comply platform at the heart of our service offering.

 

"with our recurring revenue activities continuing to perform strongly and the good momentum in q4 continued into the start of the new financial year, we are looking forward with increasing confidence.

 

"trading to the end of april 2023 is in line with our expectations

This looks like a good time to buy ?

It was 14p just a few weeks ago and maybe that big trade earlier in the week was the main reason ?

The last fund raise was ar 42p in 2022 and the recent trading update says recurring revenues per year are nearly the same as the whole market value of GRC

Thoughts welcome please

Nice start today

If anyone knows how to do charts please can they look at GRC, my basic plan is to look for when shares seem to have created a steady base price

To me it seems very low after falling 55% but if anyone like Ria can look that would be appreciated

Mny thanks Kidlington

AUGUST 8 2023

Aleta’s lead programme, ALETA-001, has clinical support from collaborator Cancer Research UK, which will initiate the Phase 1/2 clinical trial during H2 2023ALETA-001, previously granted a UK Innovation Passport, was developed to address the urgent unmet patient need of relapse after CD19 CAR T-cell cancer treatment

Aleta Biotherapeutics (Aleta), a privately-held immuno-oncology company with a platform of CAR T-cell engagers (CTE) which enable cell therapies to improve outcomes for patients with cancer, announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) to evaluate investigational biologic ALETA-001 in a Phase 1/2 clinical trial in the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T-cell therapy.

Aleta’s lead programme, ALETA-001, has clinical support from its collaboration partner, Cancer Research UK’s Centre for Drug Development, which has sponsored and will conduct the Phase 1/2 clinical trial.

We're thrilled to see

@BioAleta

’s lead programme, ALETA-001, progress to clinical trial! Leveraging our modelling capabilities, we were proud to support

@CR_UK

's early phase clinical development of ALETA-001, a CAR-T cell engager for

Lots of information there ,many thanks I will read that today , does that mean PYC will get further work directly from Cancer Research UK ?

It looks like it was a good decision to buy some MIRRI this week, thanks for all the viewpoints

What on earth are these small trades for please

PYC have recently had new collabs from Bicycle, who raised appox $240m.

They helped with Cellcentric with CCS1477 ( now inobrodib )and they have just raised approx $20m and had fast track orphan status from FDA.

Numab secured $110m funding in 2021.

You could hope that a fraction of those $ or £ raised ( at least ) could come PYC's way to help with projects either already started or in the future from these companies?

Then there is the 6m from VAL for (201) if that ever gets off the ground that is.

If you look at the Numab pipeline link i posted earlier, you can see that 8 of the 9 projects have partners, including: 3SBio/Sunshine Guojian, Boehringer Ingelheim, Eisai, CStone, Ono, Kaken, and Tillotts.

They have 1 which is fully owned by themselves which is NM32-2668

Its not out of the realms of possibilities that IF PYC are helping Numab on pipeline with a partner, then said partner could also be informed of PYC work?

No problem and good morning

Both are severely undervalued, especially the A.I cancer drug one ( see excellent postage on there from Ralph and Kidlington

£1.2mln cap with £800k cash and fully funded with some huge clients in the drug development world

It is onlyAIM listed artificial intelligence bio tech as far as I'm aware

I added some MIRI yesterday and will add some more as it seems that now the seller was out it should get back to 3p ?

Good morning Ria

This looks good ,also been adding small caps GRC and PYC

Many thanks AGBR?I will listen today

Very many thanks for taking the time to get me up to speed